Writing the Biological Script: Scaling DNA Manufacturing for the Next Generation of Therapeutics

The synthetic biology industry is increasingly focused on the challenges of scaling DNA manufacturing to meet the demands of next-generation therapeutic development. As genetic medicines move toward commercialization, the industry requires more efficient and scalable methods for synthesizing high-fidelity DNA sequences. This shift is critical for ensuring that advanced treatments, such as cell and gene therapies, can be produced reliably and cost-effectively for global patient populations.